Skip to content
PubMed This is a summary of 17 peer-reviewed journal articles Updated
Pediatric Hematology · Antiphospholipid Syndrome

Is Antiphospholipid Syndrome Inherited? Risk to Children

At a Glance

Antiphospholipid syndrome is not inherited in a simple pattern. A child may share genetic susceptibility, but most children of parents with APS remain healthy, and no validated test or percentage predicts who will develop antiphospholipid antibodies or clinical APS.

Familial antiphospholipid syndrome (APS) is not passed directly from a parent to a child in a simple or predictable way. Unlike conditions caused by a single mutated gene, familial APS involves a complex, incompletely understood genetic susceptibility [1][2]. While a child may inherit an increased tendency to develop autoimmune conditions, there is no reliable percentage, known inheritance pattern, or validated risk score to predict whether an individual child will ever develop antiphospholipid antibodies or clinical APS [3].

Understanding Complex Susceptibility

When we talk about “familial” APS, it means the condition has been observed to cluster in certain families [4][5]. However, APS is considered a polygenic condition, meaning multiple different genes interact with environmental factors to contribute to the overall risk [1].

Because of this genetic complexity, APS has uncertain penetrance. In practical terms, this means relatives may share some genetic susceptibility variants and environmental influences, but never develop antiphospholipid antibodies or the syndrome itself [2]. Medical research often proposes a second hit model to explain this: while a blood clot or pregnancy complication can happen without any identifiable trigger, environmental factors—such as an infection, surgery, pregnancy, or severe inflammation—can act as a “second hit” that activates the immune system and increases the chance of a complication [6][7].

What Does This Mean for Your Child’s Risk?

It is very common for parents with APS to worry about passing the condition to their children. However, the majority of children born to parents with APS are generally healthy [3].

When evaluating familial risk, it helps to understand the difference between genetic risk, temporary antibodies, and actual clinical APS.

Stage What It Means Next Steps / Implications
Inherited Susceptibility A child may inherit genetic variants that make their immune system slightly more prone to autoimmunity [1]. No immediate medical action is required. Having a family history does not prove a child will develop APS.
Passive Maternal Antibodies In newborns, maternal antibodies can cross the placenta. Roughly 30% of babies born to mothers with these antibodies may temporarily test positive at birth [8]. These antibodies usually fade over months. Serious neonatal blood clots are exceedingly uncommon but not impossible [8].
Developing Antibodies The child’s own immune system produces antiphospholipid antibodies. Antibodies alone are not APS [9]. They can be transient (e.g., after a childhood virus).
Clinical APS The child has specific persistent antibodies (confirmed 12 weeks apart) and experiences a qualifying clinical event (like a blood clot) [10]. Requires specialist management (e.g., pediatric hematology/rheumatology) [11].

Note for parents of newborns: If you have antiphospholipid antibodies, ask your obstetric and pediatric teams what monitoring is appropriate for your individual baby after birth [8].

Should Asymptomatic Children Be Tested?

If your child is completely healthy and shows no symptoms, medical guidelines generally do not recommend routine screening for antiphospholipid antibodies solely based on a family history of APS [12][13].

There are several reasons why preventative testing in healthy, asymptomatic children is usually discouraged:

  • Antibodies can be transient: A child might temporarily develop antiphospholipid antibodies after a standard childhood viral infection [14]. To accurately assess risk, positive tests for specific antibodies (lupus anticoagulant, anticardiolipin, or anti-beta-2-glycoprotein I) must be confirmed with a second test at least 12 weeks later [10][15].
  • Management complexities: Finding antibodies in a healthy child does not automatically mean they need blood thinners or preventative medication. While knowing about the antibodies might alter how doctors manage the child during high-risk situations (like surgery, severe illness, or prolonged immobility), routine testing often causes unnecessary anxiety without changing daily medical care [16].
  • Antibodies alone are not APS: A diagnosis requires both the persistent laboratory markers and a qualifying clinical event [9].

When Testing is a Medical Emergency

If a child develops signs of a blood clot or stroke, this is a medical emergency. Seek immediate medical attention. Do not wait for an outpatient antibody test [11][17]. Warning signs include:

  • Sudden one-sided weakness, numbness, or trouble speaking
  • Severe, unusual headache or sudden vision changes
  • Sudden shortness of breath or chest pain
  • Unexplained, sudden swelling, pain, or redness in an arm or leg

For non-emergency situations, testing may be considered if a child is diagnosed with another autoimmune disease, like childhood-onset lupus, under the guidance of a pediatric specialist [11].

The Role of Genetic Counseling

Because APS is not caused by a single identifiable gene, genetic counselors cannot offer a simple DNA test to calculate your child’s exact risk of developing the syndrome [1]. However, if you have a striking pattern of early-onset or multiple autoimmune conditions in your family (like lupus or thyroid disease), consulting with a genetic counselor can help you map out your broader risk profile and document your family history accurately.

Common questions in this guide

Is antiphospholipid syndrome directly inherited from a parent?
No. Familial APS does not follow a simple, predictable inheritance pattern caused by one gene. A child may inherit a tendency toward autoimmunity, but that does not mean the child will develop antiphospholipid antibodies or clinical APS.
What is my child’s chance of developing APS if I have it?
There is no validated percentage, inheritance pattern, or risk score that can predict an individual child’s chance of developing APS. Most children born to a parent with APS are generally healthy, and family history alone does not establish that a child will develop the condition.
Should a healthy child be screened for APS because of family history?
Routine antibody screening is generally not recommended for a healthy child solely because a parent has APS. Antiphospholipid antibodies can appear temporarily after infections, and a positive result usually needs repeat testing at least 12 weeks later; testing may be considered when symptoms or another autoimmune disease are present under specialist guidance.
Can maternal antiphospholipid antibodies affect a newborn?
Maternal antiphospholipid antibodies can cross the placenta, and about 30% of babies born to mothers with these antibodies may test positive temporarily at birth. The antibodies usually fade over several months, and serious newborn blood clots are very uncommon. The obstetric and pediatric teams can advise whether monitoring is needed.
Which symptoms in a child could signal a clot or stroke?
A child with sudden one-sided weakness or numbness, trouble speaking, a severe unusual headache, sudden vision changes, chest pain, shortness of breath, or unexplained swelling, pain, or redness in an arm or leg needs immediate medical evaluation. These symptoms are an emergency, so do not wait for an outpatient antibody test.
Can genetic counseling determine whether my child will develop APS?
There is no single-gene DNA test that can calculate a child’s exact risk of APS. Genetic counseling may still help document the family history and assess a broader pattern of early-onset or multiple autoimmune conditions, such as lupus or thyroid disease.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Are there specific symptoms or warning signs I should watch for in my child that would warrant immediate emergency medical evaluation?
  2. 2.Should my child's care team be made aware of our family history of APS before any surgeries, severe illnesses, prolonged immobility, or future use of estrogen-containing medications?
  3. 3.Given our family's specific history, would you recommend a consultation with a pediatric rheumatologist or genetic counselor?
  4. 4.Which specific antibody tests were positive in my own diagnostic profile, and should I document this for my child's future medical records?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (17)
  1. 1

    Genetics of Antiphospholipid Syndrome.

    Ortiz-Fernández L, Sawalha AH

    Current rheumatology reports 2019; (21(12)):65 doi:10.1007/s11926-019-0869-y.

    PMID: 31807905
  2. 2

    New Biomarkers for Atherothrombosis in Antiphospholipid Syndrome: Genomics and Epigenetics Approaches.

    Lopez-Pedrera C, Barbarroja N, Patiño-Trives AM, et al.

    Frontiers in immunology 2019; (10()):764 doi:10.3389/fimmu.2019.00764.

    PMID: 31040845
  3. 3

    "APS pregnancy - The offspring".

    Bitsadze V, Nalli C, Khizroeva J, et al.

    Lupus 2020; (29(11)):1336-1345 doi:10.1177/0961203320947154.

    PMID: 32752918
  4. 4

    Familial Clustering of Antiphospholipid Syndrome.

    Saadia A, Khan SH, Khan MD

    Journal of the College of Physicians and Surgeons--Pakistan : JCPSP 2019; (29(12)):1221-1224 doi:10.29271/jcpsp.2019.12.1221.

    PMID: 31839101
  5. 5

    Double trouble: myocardial infarction with non-obstructive coronary arteries as a presentation of Hughes syndrome in monozygotic twins.

    Djokovic A, Stojanovich L, Stanisavljevic N, et al.

    Lupus 2020; (29(5)):505-508 doi:10.1177/0961203320906267.

    PMID: 32041501
  6. 6

    Catastrophic antiphospholipid antibody syndrome as a first manifestation of primary antiphospholipid antibody syndrome in a middle-aged man.

    Jafry NH, Mubarak M, Ahmed E, Akhtar F

    CEN case reports 2020; (9(2)):152-158 doi:10.1007/s13730-020-00446-0.

    PMID: 31989453
  7. 7

    Acute adrenal insufficiency due to adrenal hemorrhage complicating colorectal surgery: Report of two cases and correlation with the antiphospholipid antibody syndrome.

    Kolinioti A, Tsimaras M, Stravodimos G, Komporozos V

    International journal of surgery case reports 2018; (51()):90-94 doi:10.1016/j.ijscr.2018.07.034.

    PMID: 30145500
  8. 8

    Neonatal antiphospholipid syndrome-associated thrombosis: Diagnostic pitfalls and therapeutic frontiers.

    Tzatzadaki-Amantou E, Lianou A, Tsantes AG, et al.

    Blood reviews 2026; 101433 doi:10.1016/j.blre.2026.101433.

    PMID: 42731915
  9. 9

    16th International Congress on Antiphospholipid Antibodies Task Force Report on Antiphospholipid Syndrome Treatment Trends.

    Cohen H, Cuadrado MJ, Erkan D, et al.

    Lupus 2020; (29(12)):1571-1593 doi:10.1177/0961203320950461.

    PMID: 33100166
  10. 10

    Cardiac Manifestations of Antiphospholipid Syndrome: Clinical Presentation, Role of Cardiac Imaging, and Treatment Strategies.

    Tufano A, Di Minno MND, Guida A, et al.

    Seminars in thrombosis and hemostasis 2019; (45(5)):468-477 doi:10.1055/s-0039-1692702.

    PMID: 31216589
  11. 11

    Managing Antiphospholipid Syndrome in Children and Adolescents: Current and Future Prospects.

    Islabão AG, Trindade VC, da Mota LMH, et al.

    Paediatric drugs 2022; (24(1)):13-27 doi:10.1007/s40272-021-00484-w.

    PMID: 34904182
  12. 12

    The 2023 ACR/EULAR Antiphospholipid Syndrome Classification Criteria.

    Barbhaiya M, Zuily S, Naden R, et al.

    Arthritis & rheumatology (Hoboken, N.J.) 2023; (75(10)):1687-1702 doi:10.1002/art.42624.

    PMID: 37635643
  13. 13

    Antiphospholipid syndrome and its role in pediatric cerebrovascular diseases: A literature review.

    Sarecka-Hujar B, Kopyta I

    World journal of clinical cases 2020; (8(10)):1806-1817 doi:10.12998/wjcc.v8.i10.1806.

    PMID: 32518771
  14. 14

    Antiphospholipid Antibody Testing: An Audit on Testing Practices in a Public Tertiary Care Center.

    Mansory EM, Alahwal HM, Bahashwan SM, et al.

    Journal of clinical medicine 2023; (13(1)) doi:10.3390/jcm13010243.

    PMID: 38202249
  15. 15

    Key Issues at the Forefront of Diagnosis and Testing for Antiphospholipid Syndrome.

    Qiao J, Bailly J, Opie J

    Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis 2024; (30()):10760296241306751 doi:10.1177/10760296241306751.

    PMID: 39692090
  16. 16

    EULAR recommendations for the management of antiphospholipid syndrome in adults.

    Tektonidou MG, Andreoli L, Limper M, et al.

    Annals of the rheumatic diseases 2019; (78(10)):1296-1304 doi:10.1136/annrheumdis-2019-215213.

    PMID: 31092409
  17. 17

    Non-Criteria Manifestations of Juvenile Antiphospholipid Syndrome.

    Miyamae T, Kawabe T

    Journal of clinical medicine 2021; (10(6)) doi:10.3390/jcm10061240.

    PMID: 33802787

This page is for informational purposes only and does not constitute medical advice. Ask your child’s pediatrician or a pediatric hematologist or rheumatologist about your family’s situation and any urgent symptoms.

Get notified when new evidence is published on familial antiphospholipid syndrome.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.